Improving the Therapeutic Index of Proinflammatory Cytokines for Cancer Immunotherapy Werewolf Therapeutics, Inc., is an ...

BDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent ...

A study of more than 100 patients found that immunotherapy can cure a rare type of cancer in various tumor sites without ...

Immunity is not a function most people particularly associate with the liver. But because of its connection to the gut, the ...

The immune system can work in two ways: the innate immune system reacts to any foreign invaders that are identified by immune cells that look... | Cell And Molecular Biology ...

Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer ...

WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year - - First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking ...

During the second half of 2025, Werewolf plans to present interim data from the monotherapy and combination expansion arms, including tolerability, response rate, and durability, and to engage with ...

The leading Merkel Cell Carcinoma Companies such as ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte ...

This study exploring the role of TRPV1 signaling in recruiting macrophages and promoting angiogenesis during tympanic membrane wound healing presents useful findings. However, the strength of evidence ...

Newly discovered oncology drugs called “DNA-encoded tri-specific T-cell engagers,” or “DTriTEs,” engage the immune system ...

Mohammed Milhem, MBBS discussed the mechanism of action of RP1, the design and preliminary findings of the IGNYTE trial in ...